Alnylam (ALNY) Q2 2026 earnings review
AMVUTTRA Crosses $1B, But Fading Switcher Bolus Forces Guidance Cut
Alnylam delivered a fundamentally strong Q2 2026, posting $1.17B in total net product revenues (+74% YoY) and generating $164M in GAAP net income. AMVUTTRA officially reached blockbuster status in a single quarter ($1.01B). However, the underlying narrative shifted negatively: management cut FY26 TTR product revenue guidance by $200M at the midpoint. This confirms that the initial launch hyper-growth—fueled by pent-up demand from patients switching off older stabilizer therapies—is decelerating. Alnylam must now rely on organic, first-line patient acquisition in an increasingly competitive ATTR-CM market.
🐂 Bull Case
The company has successfully transitioned from a cash-burning biotech to a structurally profitable enterprise, generating $318M in non-GAAP operating income in Q2 alone (+233% YoY).
AMVUTTRA revenues doubled YoY to $1.01B in the quarter. With HELIOS-B outcomes data validating its profile, it remains the clear market leader in the ATTR space, with increasing international traction.
🐻 Bear Case
The TTR guidance cut validates earlier fears that initial AMVUTTRA launch metrics were inflated by a massive 'bolus' of second-line patients switching from tafamidis. Going forward, growth will be harder to achieve.
As AMVUTTRA scales, its tiered royalty structure payable to Sanofi is eroding gross margins. COGS jumped to 25.4% of product revenues, up significantly from 21.1% a year ago.
⚖️ Verdict: 🔴
Bearish. While trailing numbers are spectacular, markets price future expectations. Cutting the revenue guidance for your flagship franchise mid-year indicates a tangible deceleration in demand momentum.
Key Themes
TTR Franchise Guidance Cut Signals Deceleration
Management revised full-year 2026 TTR Net Product Revenue guidance down to $4.2B-$4.5B from the prior $4.4B-$4.7B. They explicitly cited 'normalization of growth in second line volume after satisfying pent-up demand.' This means the easy growth from capturing competitors' existing patients is reversing, and the company must now grind out first-line market expansion to meet its 2030 targets.
Gross Margin Deterioration
Cost of Goods Sold (COGS) as a percentage of net product revenues increased sharply to 25.4% in 26Q2, up from 21.1% in 25Q2 and 20% in 26Q1. The root cause is the success of AMVUTTRA itself—higher sales volumes trigger higher blended royalty rate tiers payable to Sanofi. This structural headwind will persist, capping gross margin expansion regardless of pricing power.
AI Integration to Drive ATTR-CM Diagnoses
With the switcher bolus fading, Alnylam is actively investing in expanding the total addressable market. They announced a strategic collaboration with a large California health system (4.5M+ members) utilizing 'Invision Precision Cardiac Amyloid'—an FDA-cleared, AI-enabled echocardiography tool—to find undiagnosed patients. This pairs with their newly announced Komodo Health scaling, aggressively pushing tech-enabled first-line patient acquisition.
Collaboration and Royalty Revenues Surging
While product revenue guidance was cut, management significantly raised Collab & Royalty revenue guidance by $150M at the midpoint (to $575M-$625M). This accelerating trend is driven by higher reimbursable development activities with Roche for the ZENITH Phase 3 trial, alongside growing royalties from Novartis's Leqvio.
Deep Pipeline Progression: Beyond TTR
Alnylam is aggressively mitigating single-franchise risk by moving its pipeline forward. Notable Q2 progress includes initiating Phase 2 trials for ALN-6400 (von Willebrand disease) and mivelsiran (Down syndrome-associated Alzheimer's), plus a Phase 1 for ALN-6222 targeting inhibin E (INHBE) for obesity. The Alzheimer's data is especially encouraging, showing robust Aβ42 reductions up to 30 months without ARIA risks.
Other KPIs
Accelerating YoY (+89%), but showing signs of sequential deceleration as ONPATTRO revenues collapse (-65% YoY to $18M) due to AMVUTTRA cannibalization, and AMVUTTRA growth normalizes. U.S. TTR revenues drove most of the growth ($106M QoQ increase), but $20M of this was offset by inventory impacts and a modest net price reduction.
Stable. The rare disease segment (GIVLAARI and OXLUMO) posted solid 11% YoY growth, matching the exact same 11% growth profile seen in previous periods. This provides a steady, predictable cash flow stream outside the volatile TTR cardiomypathy battlefield.
Up from $2.9 billion at the end of FY25. The company generated strong net cash from operating activities, easily covering $59M in interest payments tied to Leqvio royalty sales and development funding. The balance sheet provides immense flexibility to scale R&D.
Guidance
Decelerating. Cut from prior guidance of $4.4-$4.7B. This $200M midpoint reduction officially acknowledges that the aggressive patient-switching momentum seen in early 2025/late 2026 has slowed. Alnylam must now rely on slower, organic diagnosis and first-line starts.
Accelerating. Raised significantly from the previous $400-$500 million target. The $150M bump at the midpoint offsets the majority of the TTR product revenue guidance cut, largely driven by the Roche partnership (zilebesiran development) and Leqvio royalties.
Decelerating. Lowered from the previous forecast of 64% to 77%. While nearly 60%+ organic growth is exceptional for a large-cap biotech, the downward revision resets market expectations regarding the terminal velocity of the AMVUTTRA launch.
Key Questions
Quantifying the First-Line Shift
With the second-line switcher bolus officially exhausted, what is the current run-rate of true, first-line treatment naive patient starts, and what percentage of total new starts do they represent?
Gross Margin Floor
COGS jumped to 25.4% of product revenues this quarter due to AMVUTTRA royalty tiers. At what annual sales threshold does the royalty rate to Sanofi max out, and where do you expect gross margins to stabilize in 2027?
Pricing Power & Ex-U.S. Headwinds
You noted a modest reduction in net price in the U.S. in Q2. Combined with earlier European price cuts for the CM indication, what is the cumulative gross-to-net impact expected for the remainder of the year?
China Commercialization Timeline
Regarding the exclusive agreement with BeOne Medicines for AMVUTTRA in China, what are the expected regulatory timelines for marketing authorization, and how is the revenue/royalty split structured?